A multicenter single‐arm trial of neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2‐positive breast cancer

Abstract The objective of this multicenter, single‐arm trial (ChiCTR1900022293) was to explore the efficacy and safety of neoadjuvant therapy with epirubicin, cyclophosphamide, and pyrotinib followed by docetaxel, trastuzumab, and pyrotinib (ECPy‐THPy) in the treatment of patients with stage II–III...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Qiyun Shi, Xiaowei Qi, Peng Tang, Linjun Fan, Li Chen, Shushu Wang, Yan Liang, Ying Hu, Minghao Wang, Lin Ren, Guozhi Zhang, Xuanni Tan, Long Yuan, Junze Du, Xiujuan Wu, Mengyuan Wang, Hongying Che, Pengwei Lv, Dejie Chen, Jinhui Hu, Qiuyun Li, Yanwu Zhang, Kunxian Yang, Yuan Zhong, Chuang Chen, Zemin Zhou, Liyuan Qian, Jingwei Zhang, Mingde Ma, Yi Sun, Yi Zhang, Jun Jiang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2023-12-01
coleção:	MedComm
Assuntos:	HER2‐positive breast cancer multicenter study neoadjuvant therapy pyrotinib trastuzumab
Acesso em linha:	https://doi.org/10.1002/mco2.435
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!